Anzeige
Mehr »
Login
Freitag, 16.04.2021 Börsentäglich über 12.000 News von 661 internationalen Medien
Top-Rendite fürs Depot: Superfood und Psychedelika-Medikamente!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
201 Leser
Artikel bewerten:
(1)

GreenLight Biosciences Welcomes Mark Singleton As Lead For Plant Health Innovation

BOSTON, March 3, 2021 /PRNewswire/ -- GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design and manufacturing for human, animal and plant health, today announced the appointment of Mark Singleton as the company's Senior Vice President of Technology and External Innovation.

"GreenLight is working to address humanity's greatest challenges, from producing vaccines to protecting bees," said Andrey Zarur, CEO of GreenLight. "Mark brings the experience and expertise we need to advance towards our goal of feeding the world's growing population while protecting the planet."

Singleton will report to Andrey Zarur and lead on plant health innovations such as GS2, GreenLight's RNA-based Colorado potato beetle control product.

Founded in 2008, GreenLight has raised $230M to date and is rapidly expanding to new market opportunities in human health, animal health and plant health. Last year, GreenLight raised $100M+ in an oversubscribed series D round to accelerate efforts around a COVID-19 vaccine and messenger RNA manufacturing.

Key investors include Morningside, Baird Capital, Cormorant Asset Management, Fall Line, S2G Ventures, Lupa Systems Capital, Continental Grain Company and Prelude Ventures.

"I'm extremely excited to be joining the team to help GreenLight realize its mission," Singleton said. "It's critical for the world to produce more food more sustainably, and GreenLight will help this happen."

Singleton joins GreenLight from UPL Ltd where he was The Global Head of New Technologies.

Mark worked on UPL's integration of Arysta, assembled a world class team of scientists, and managed the building of the OpenAg Center in the Research Triangle Park, a 69,000 sq ft multi-functional R&D facility dedicated to the support of VC funded companies bringing their technologies from discovery to the market across all indications and technology platforms.

In this role, Mark became a key player in sourcing and characterising new and disruptive technologies for use in agriculture, using platforms selected from VC funded companies around the world.

During his time with Arysta LifeScience, Mark was appointed as their first ever VP of R&D and Regulatory and oversaw a multi-year program that increased the value of their R&D portfolio five-fold and doubled the contribution of BioSolutions within that portfolio.

About GreenLight Biosciences, Inc.

GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible. GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection and support the health of bees and other pollinators. The GreenLight team values diversity, inclusion, and equality and promises to use collaboration to remain scientifically imaginative and passionately focused on making a difference in the world. For more information, visit https://www.greenlightbiosciences.com

Photo - https://mma.prnewswire.com/media/1448332/GreenLight_Biosciences_Mark_Singleton.jpg

Kostenloser Wertpapierhandel auf Smartbroker.de
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.